Center of Experimental Therapeutics, Department of Oncology.-Coordinate and supervise translational research projects of internal phase I cell therapy trials from the Tumor Microenvironment and Biomarker Discovery HiTIDE lab.- Research in immuno-oncology: dissect mechanisms of T cell exclusion and immune-resistance in the tumor microenvironment for next generation adoptive cell therapy development.

Center of Experimental Therapeutics, Department of Oncology.- Data analysis and quality control of immunological assays for internal pre-clinical/clinical studies.- Research in immuno-oncology: dissect mechanisms of T cell exclusion and immune-resistance in the tumor microenvironment for next generation adoptive cell therapy development.

- Evaluation of novel technologies and initiation of collaborations with companies in the field of cancer diagnostic & monitoring in liquid biopsy- Scientific support to the Personalized Medicine department for pre-clinical drug development and biomarker discovery

Institute of Molecular Engineering. P.I: Prof. Jeffrey Alan Hubbell. - Relocation of the laboratory, technology transfer and training of PhD students- Design of a novel platform for induction of antigen-specific immune tolerance through targeting of the antigen to apoptotic cells scavenger receptors

Laboratory of Regenerative Medicine and Pharmacobiology, Merck Serono Chair in Drug Delivery. P.I: Prof. Jeffrey Alan Hubbell.Thesis in the applied immuno-engineering research field.In collaboration with laboratory technicians, chemists and bioengineers:- Participated to the development of an innovative antigen-specific immunotherapy. Engineered protein constructs, designed methods and protocols to assess the potential of the technology for treatment of autoimmunity, understand the mechanisms involved in this process and characterize the state of tolerance induced- Helped on the design of a co-adjuvanted vaccine for treatment of chronic hepatitis B and cancer

Institute of Bioengineering, MIT. PI: Professor Linda Griffith. "Phenotypic response of human mesenchymal stem cells to bivalent ErbB ligands". - Evaluated the phenotypic response of human mesenchymal stem cells exposed to bivalent ErbB ligands, aiming at enhancing bone differentiation.

Laboratory of Biomedical Orthopaedics, EPFL. P.I: Professor Dominique Pioletti.Development of a gel form of ECM-scaffold prepared from bovine Nucleus Pulposus for application in joint repair.